Published in Drug Metab Pharmacokinet on November 12, 2010
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes Metab Syndr Obes (2013) 0.91
Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy. Clin Med Insights Endocrinol Diabetes (2012) 0.80
Linagliptin: A thorough Characterization beyond Its Clinical Efficacy. Front Endocrinol (Lausanne) (2013) 0.80
Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials. Ther Adv Endocrinol Metab (2012) 0.77
Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. Drugs R D (2014) 0.76
Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. J Diabetes Investig (2016) 0.75
Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes. Diabetes Metab Syndr Obes (2012) 0.75
Efficacy and safety of linagliptin (tradjenta) in adults with type-2 diabetes mellitus. P T (2011) 0.75
The diagnostic value of symptoms for colorectal cancer in primary care: a systematic review. Br J Gen Pract (2011) 3.79
Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol (2011) 3.50
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest (2014) 3.10
Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol (2003) 2.77
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol (2012) 2.17
Clinical features of bladder cancer in primary care. Br J Gen Pract (2012) 1.89
The junctional adhesion molecule (JAM) family members JAM-2 and JAM-3 associate with the cell polarity protein PAR-3: a possible role for JAMs in endothelial cell polarity. J Cell Sci (2003) 1.84
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol (2014) 1.75
The effect of hydrogen sulfide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. Antioxid Redox Signal (2010) 1.72
Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care (2012) 1.63
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care (2014) 1.60
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol (2012) 1.60
Acute infective conjunctivitis in primary care: who needs antibiotics? An individual patient data meta-analysis. Br J Gen Pract (2011) 1.59
Pathways to the diagnosis of colorectal cancer: an observational study in three UK cities. Fam Pract (2005) 1.59
Development and evaluation of a brief self-completed family history screening tool for common chronic disease prevention in primary care. Br J Gen Pract (2013) 1.45
Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord (2011) 1.36
Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care (2013) 1.26
The surgical management of sacral chordomas. Spine (Phila Pa 1976) (2009) 1.24
Will widgets and semantic tagging change computational biology? PLoS Comput Biol (2010) 1.21
Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study. Diabetes Care (2013) 1.19
Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab (2010) 1.17
Prospective study of elderly people comparing treatments following first primary care consultation for a symptomatic hip or knee. Fam Pract (2004) 1.14
Survivors of uterine cancer empowered by exercise and healthy diet (SUCCEED): a randomized controlled trial. Gynecol Oncol (2012) 1.14
S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway. J Cardiovasc Pharmacol (2009) 1.13
Impact of persistent hip or knee pain on overall health status in elderly people: a longitudinal population study. Arthritis Rheum (2005) 1.12
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol (2014) 1.12
Protective effects of cysteine analogues on acute myocardial ischemia: novel modulators of endogenous H(2)S production. Antioxid Redox Signal (2010) 1.10
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J (2013) 1.09
Clinical features of kidney cancer in primary care: a case-control study using primary care records. Br J Gen Pract (2013) 1.09
Evaluation of a tailored intervention to improve management of overweight and obesity in primary care: study protocol of a cluster randomised controlled trial. Trials (2014) 1.08
Views of cancer care reviews in primary care: a qualitative study. Br J Gen Pract (2011) 1.08
A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol (2012) 1.06
Peroxynitrite mediates calcium-dependent mitochondrial dysfunction and cell death via activation of calpains. FASEB J (2004) 1.06
Population survey comparing older adults with hip versus knee pain in primary care. Br J Gen Pract (2005) 1.05
Diagnosis using "test of treatment". BMJ (2009) 1.03
Hypoxia-inducible factor-1α is involved in the pro-angiogenic effect of hydrogen sulfide under hypoxic stress. Biol Pharm Bull (2010) 1.03
Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol (2012) 1.00
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol (2002) 0.99
In the absence of evidence, who chooses? A qualitative study of patients' needs after treatment for colorectal cancer. J Health Serv Res Policy (2004) 0.97
Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial. Curr Med Res Opin (2013) 0.97
Intrathoracic fracture-dislocation of the proximal humerus: a case report and report of a new surgical technique. J Trauma (2007) 0.95
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J (2013) 0.95
Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. Am J Ther (2013) 0.95
Malignant transformation of acoustic neuroma/vestibular schwannoma 10 years after gamma knife stereotactic radiosurgery. Skull Base (2010) 0.94
The Coenzyme Q10 analog decylubiquinone inhibits the redox-activated mitochondrial permeability transition: role of mitcohondrial [correction mitochondrial] complex III. J Biol Chem (2003) 0.94
"I wish I'd told them": a qualitative study examining the unmet psychosexual needs of prostate cancer patients during follow-up after treatment. Patient Educ Couns (2010) 0.94
Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther (2012) 0.93
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin Pharmacokinet (2010) 0.92
Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin (2012) 0.92
Partners and close family members of long-term cancer survivors: health status, psychosocial well-being and unmet supportive care needs. Psychooncology (2011) 0.92
Hydrogen sulfide is an endogenous regulator of aging in Caenorhabditis elegans. Antioxid Redox Signal (2013) 0.92
Histologic follow-up of atypical endocervical cells. Liquid-based, thin-layer preparation vs. conventional Pap smear. Acta Cytol (2002) 0.91
Hypochlorous acid-mediated mitochondrial dysfunction and apoptosis in human hepatoma HepG2 and human fetal liver cells: role of mitochondrial permeability transition. Free Radic Biol Med (2005) 0.90
DISCERN-Genetics: quality criteria for information on genetic testing. Eur J Hum Genet (2006) 0.89
Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovasc Diabetol (2013) 0.89
Thrombosis and cancer. Nat Rev Clin Oncol (2012) 0.88
Ibuprofen extrudate, a novel, rapidly dissolving ibuprofen formulation: relative bioavailability compared to ibuprofen lysinate and regular ibuprofen, and food effect on all formulations. J Clin Pharmacol (2005) 0.87
The pro-inflammatory oxidant hypochlorous acid induces Bax-dependent mitochondrial permeabilisation and cell death through AIF-/EndoG-dependent pathways. Cell Signal (2006) 0.87
The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol (2013) 0.87
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol (2008) 0.86
Evaluation of a self-administered oral glucose tolerance test. Diabetes Care (2013) 0.86
The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. Br J Clin Pharmacol (2011) 0.86
C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care (2014) 0.84
A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther (2013) 0.84
Oncologic conditions that simulate common sports injuries. J Am Acad Orthop Surg (2014) 0.84
Bowel cancer screening in England: a qualitative study of GPs' attitudes and information needs. BMC Fam Pract (2006) 0.83
Statistical characterization of QT prolongation. J Biopharm Stat (2010) 0.83
Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther (2013) 0.82
Pain and overall health status in older people with hip and knee replacement: a population perspective. J Public Health (Oxf) (2006) 0.82
Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials. J Diabetes Complications (2013) 0.82
Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia (2014) 0.82
Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis. Curr Med Res Opin (2014) 0.80
Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation. Pharm Stat (2010) 0.80
A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther (2011) 0.80
Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study. Clin Drug Investig (2011) 0.80
Nitrite-mediated protection against hypochlorous acid-induced chondrocyte toxicity: a novel cytoprotective role of nitric oxide in the inflamed joint? Arthritis Rheum (2003) 0.80
Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. Int J Clin Pharmacol Ther (2012) 0.79
Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival. Obstet Gynecol Int (2013) 0.79
Mass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C virus NS3/4 protease inhibitor, in healthy male subjects. Antimicrob Agents Chemother (2014) 0.79
Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus. Br J Clin Pharmacol (2013) 0.78
Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. Int J Clin Pharmacol Ther (2014) 0.78
beta-Phenylethyl isothiocyanate mediated apoptosis: a proteomic investigation of early apoptotic protein changes. Proteomics (2005) 0.78
More on thromboprophylaxis: quantifying risk for venous thromboembolism. Thromb Haemost (2009) 0.78
Residuals and outliers in replicate design crossover studies. J Biopharm Stat (2010) 0.78
Delayed effects in the exposure-response analysis of clinical QTc trials. J Biopharm Stat (2012) 0.78
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol (2004) 0.77